The neural cell adhesion molecule, CD56, is expressed on acute myelogenous leukemia
(AML) cells in 17–20% of the patients. However, the clinical and biological significance of its …

We investigated the expression of CD56 (a neural cell adhesion molecule, NCAM) and
CD57 in various hematopoietic and non-hematopoietic malignant cells, using Leu-19 and …

Eleven patients whose myeloblasts expressed the CD7 antigen were identified among 48
consecutive cases of AML (22.9%). Only one patient's blasts expressed other T-cell markers …

CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic
phenotype and resistance to induction therapy but no inferior survival after risk-adapted …

Abstract Abstract 4880 Background: The CD56 is a neural cell adhesion molecule (N-CAM)
expressed in natural killer cells. CD56 expression on the surface of leukemic cells in acute …

Introduction: In B‐cell acute lymphoblastic leukemia (B‐ALL), testing at diagnosis for
BCR/ABL1 gene rearrangements is mandatory for prognostic stratification and treatment …

A subgroup of patients with core binding factor acute myeloid leuke-mias (AML) is
characterized by the presence of the fusion gene CBFb-Myh11. At the cytogenetic level …

CD7 antigen, a T‐cell lineage associated antigen, is expressed in a minority of patients with
acute myeloid leukemia (AML). The biologic and clinical significance of this finding is not …

Immunophenotyping by flow cytometry is widely used in the diagnosis and subclassification
of acute myeloid leukemia (AML). CD14 is the monocyteassociated antigen most widely …

CD10 is common in B-precursor acute lymphoblastic leukemia (ALL) but is rare in acute
myeloid leukemia (AML). However, until recently, analysis for CD10 has generally required …